Cargando…

Driving better and safer HER2-specific CARs for cancer therapy

Given the clinical efficacy of chimeric antigen receptor (CAR)-based therapy in hematological malignancies, CAR T-cell therapy for a number of solid tumors has been actively investigated. Human epidermal growth factor receptor 2 (HER2) is a well-established therapeutic target in breast, as well as o...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xianqiang, Zhang, Nan, Shi, Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617544/
https://www.ncbi.nlm.nih.gov/pubmed/28977984
http://dx.doi.org/10.18632/oncotarget.17528
_version_ 1783267012481384448
author Liu, Xianqiang
Zhang, Nan
Shi, Huan
author_facet Liu, Xianqiang
Zhang, Nan
Shi, Huan
author_sort Liu, Xianqiang
collection PubMed
description Given the clinical efficacy of chimeric antigen receptor (CAR)-based therapy in hematological malignancies, CAR T-cell therapy for a number of solid tumors has been actively investigated. Human epidermal growth factor receptor 2 (HER2) is a well-established therapeutic target in breast, as well as other types of cancer. However, HER2 CAR T cells pose a risk of lethal toxicity including cytokine release syndrome from “on-target, off-tumor” recognition of HER2. In this review, we summarize the development of conventional HER2 CAR technology, the alternative selection of CAR hosts, the novel HER2 CAR designs, clinical studies and toxicity. Furthermore, we also discuss the main strategies for improving the safety of HER2 CAR-based cancer therapies.
format Online
Article
Text
id pubmed-5617544
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56175442017-10-03 Driving better and safer HER2-specific CARs for cancer therapy Liu, Xianqiang Zhang, Nan Shi, Huan Oncotarget Review Given the clinical efficacy of chimeric antigen receptor (CAR)-based therapy in hematological malignancies, CAR T-cell therapy for a number of solid tumors has been actively investigated. Human epidermal growth factor receptor 2 (HER2) is a well-established therapeutic target in breast, as well as other types of cancer. However, HER2 CAR T cells pose a risk of lethal toxicity including cytokine release syndrome from “on-target, off-tumor” recognition of HER2. In this review, we summarize the development of conventional HER2 CAR technology, the alternative selection of CAR hosts, the novel HER2 CAR designs, clinical studies and toxicity. Furthermore, we also discuss the main strategies for improving the safety of HER2 CAR-based cancer therapies. Impact Journals LLC 2017-04-29 /pmc/articles/PMC5617544/ /pubmed/28977984 http://dx.doi.org/10.18632/oncotarget.17528 Text en Copyright: © 2017 Liu et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Liu, Xianqiang
Zhang, Nan
Shi, Huan
Driving better and safer HER2-specific CARs for cancer therapy
title Driving better and safer HER2-specific CARs for cancer therapy
title_full Driving better and safer HER2-specific CARs for cancer therapy
title_fullStr Driving better and safer HER2-specific CARs for cancer therapy
title_full_unstemmed Driving better and safer HER2-specific CARs for cancer therapy
title_short Driving better and safer HER2-specific CARs for cancer therapy
title_sort driving better and safer her2-specific cars for cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617544/
https://www.ncbi.nlm.nih.gov/pubmed/28977984
http://dx.doi.org/10.18632/oncotarget.17528
work_keys_str_mv AT liuxianqiang drivingbetterandsaferher2specificcarsforcancertherapy
AT zhangnan drivingbetterandsaferher2specificcarsforcancertherapy
AT shihuan drivingbetterandsaferher2specificcarsforcancertherapy